Belgium’s UCB Names CEO-Elect, Highlights R&D In SLE, Osteoporosis
This article was originally published in The Pink Sheet Daily
With its new CEO-designate named a week ago and a promising pipeline of early- and late-stage products, Belgium’s mid-sized European pharmaceutical company UCB wants to move beyond patent cliffs and restructuring to concentrate on the potential of its R&D.
You may also be interested in...
Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with Duchenne muscular dystrophy.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.